expressing MDC (AdMDC) and assessed the ability of these MDC-modified DCs to induce immunity against a lethal respiratory challenge with Pseudomonas aeruginosa. The data demonstrate that immunization with AdMDCmodified DCs pulsed with heat-killed P. aeruginosa renders mice resistant to the lethal infection of Pseudomonas with a Th2-dominant humoral immune response in a microbe-specific manner.
Methods
Mice. Six-to eight-week-old female wild-type, CD4 + T cell-deficient (C57BL/6-CD4 tm1Mak ), CD8 + T cell-deficient (C57BL/6-CD8a tm1Mak ), B cell-deficient (C57BL/6-Igh-6 tm1Cgn ), MHC class I-deficient (C57BL/6-B2m tm1Unc ), IL-4-deficient (C57BL/6-Il4 tm1Cgn ), IL-12-deficient (C57BL/6-Il12b tm1Jm ) C57BL/6 mice and wild-type BALB/c mice (The Jackson Laboratory, Bar Harbor, Maine, USA) and MHC class II-deficient C57BL/6 mice (C57BL/6-Abb tm1 ; Taconic Farms, Germantown, New York, USA) were housed under specific pathogen-free conditions until infection.
Ad vectors. The E1 -, E3 -Ad vectors based on human Ad5 genome used in this study included AdMDC, expressing the human MDC cDNA under the control of the cytomegalovirus (CMV) early-immediate promoter/enhancer, and the AdNull, an identical vector, but with no transgene (5, 20) . Both Ad vectors were prepared as described previously and were free of replication competent Ad (21) (22) (23) .
DCs. Bone marrow-derived DCs from C57BL/6 or BALB/c mice were grown in complete RPMI-1640 media (10% FBS and antibiotics) supplemented with recombinant murine GM-CSF (10 ng/ml; R&D Systems , Minneapolis, Minnesota, USA) and recombinant murine IL-4 (2 ng/ml; R&D Systems Inc.) (24, 25) . DCs were genetically modified with AdMDC, using AdNull and PBS, pH 7, as controls, at an moi of 100 for 4 hours, washed, and then cultured for 48 hours at 37°C.
DC expression of MDC. To demonstrate that AdMDC expressed MDC at the mRNA level, total cellular RNA was extracted from the AdMDC-modified (or control-modified) DCs using TRIzol (Life Technologies Inc., Grand Island, New York, USA), and RNA (1 µg) was subjected to reverse transcription using oligo(dT) 18 primer (CLON-TECH Laboratories Inc., Palo Alto, California, USA) at 42°C in a total volume of 20 µl. The PCR reaction was performed with the following specific primers and the serial dilution (2 µl) of RT reaction mixture using AdvanTaq Plus DNA polymerase (CLONTECH Laboratories Inc.): for exogenous MDC, 5′-TGCCAAGAGTGACGTGTCCA-3′ and 5′-AGAGTAGGATCCTCATTGGCTCAGCTTATT-3′; for endogenous MDC, 5′-GTGGCTCTCGTCCTTCTTGC-3′ and 5′-GGACAGTTTATGGAGTAGCTT-3′; for control GAPDH, 5′-ATGGTGAAGGTCGGTGTGAACGGA-3′ and 5′-TTACTC-CTTGGAGGCCATGTAGGC-3′. The amplification profile was 95°C for 1 minute, 30 cycles of 95°C for 30 seconds, and 68°C for 90 seconds, followed by 68°C for 3 minutes.
To demonstrate the function of the MDC protein expressed by the AdMDC-modified DCs, human T lymphocyte CEM cells or murine T lymphocyte EL4 cells (no. CCL-119 and TIB-39, respectively; American Type Culture Collection, Manassas, Virginia, USA) were suspended in 100 µl of RPMI-1640 media containing 1 mg/ml BSA at 10 7 cells/ml and loaded to the upper wells of 5-µm pore, polycarbonate, transwell chambers in 24-well plates (Corning Costar Inc., Corning, New York, USA). Serially diluted culture supernatant of DCs genetically modified as described above was placed in the lower well in a volume of 600 µl. Where indicated, neutralizing anti-human MDC mAb or isotype-matched mouse IgG control Ab (R&D Systems Inc.) was added to the condition medium in the lower chamber at 10 µg/ml, or recombinant human MDC or recombinant human TARC (R&D Systems Inc.) was added to the cell suspension in the upper chamber at 100 ng/ml. After a 4-hour incubation at 37°C, the number of migrating cells in the lower chamber was determined by FACS analysis. A migration index was calculated as the number of cells migrating in the presence of conditioned media divided by the number of cells migrating in the presence of medium only (26) (27) (28) .
To assess the in vivo chemoattracting activity of AdMDC-modified DCs for cells expressing CCR4, a receptor for MDC, DCs were labeled with PKH26 (Zynaxis, Cell Science Inc., Malvern, Pennsylvania, USA) after AdMDC or AdNull modification and injected intravenously to C57BL/6 mice. Four days after the injection, spleens were dissected, and frozen sections (5 µm thick) were incubated with rabbit anti-mouse CCR4 Ab diluted at 1:500 (Alexis Corp., San Diego, California, USA). The specimens were then treated with 20 µg/ml anti-rabbit IgG FITC Ab (Vector Laboratories, Burlingame, California, USA), followed by nuclear staining with 1 µg/ml 4′, 6-diamidino-2-phenylindole (DAPI; Dojindo Laboratories, Tokyo, Japan).
Assessment of DCs by flow cytometry. DCs were incubated with the FITC-and phycoerythrin-conjugated (PEconjugated) mAbs against the surface molecules CD40 and I-A b (MHC class II), CD86 (B7-2), and CD80 (B7-1), or appropriate isotype-matched control Ab (PharMingen, San Diego, California, USA). Stained cells were analyzed by a contour plot of 530 nm for FITC and 585 nm for PE, and 1% of false positive events was accepted in the control Ab staining.
Bacterial strains and immunization. P. aeruginosa strains used in this study (all generously provided by A. Prince, Columbia University, New York, New York, USA) included the well-characterized laboratory strains (referred here as "laboratory strains") PAO1 (serogroup O2), PAO-NP (Pil -mutant of PAO1), PAK (serogroup O1), and PA103 (serogroup O11). In addition, several other strains (referred here as "clinical strains") cultured from the sputum of individuals with cystic fibrosis included PA514 (Fla + , Pil + ), PA515 (Fla + , Pil + ), PA516 (Fla -, Pil + ), and PA517 (Fla -, Pil + ). DCs were incubated with AdMDC, AdNull, or PBS at an moi of 100 for 4 hours at 37°C in the presence of heat-killed (56°C, 30 minutes) P. aeruginosa or (as a control) Escherichia coli (25922 strain; ATCC) at a ratio of ten bacteria per one DC. DCs were incubated for a further 30 minutes with 200 µg/ml gentamicin sulfate to kill the remaining bacteria, washed extensively with PBS, and injected intravenously at 10 5 cells per mouse. Where indicated, genetically modified DCs pulsed with heat-killed P. aeruginosa were incubated with 10 µg/ml anti-mouse CD40 Ab (PharMingen) for 2 hours before injection. AdMDC-and AdNull-modified DCs were shown to be capable of equally loading an antigen as naive DCs because all of the DCs equally stimulated IL-4 secretion from ovalbumin-specific (OVA-specific) Th2 cells (provided by M. Ono, Sendai, Tohoku University, Japan) in the presence of 50 µg/ml OVA (Sigma Chemical Co., St. Louis, Missouri, USA) (not shown).
Anti-pseudomonas Ab's. Ab's in sera were assessed by ELISA in microtiter plates (Bio-Rad Laboratories Inc., Hercules, California, USA) coated with 10 7 CFU heatkilled PAO1 per well using Mouse Typer sub-isotyping kit (Bio-Rad Laboratories Inc.) (29) . End-point titers were determined as the inverse of the dilution that gave a fixed absorbance value of 0.1 at OD 415 . Negative results were given a titer of 20, the starting dilution.
Infection of mice. Lethal respiratory infection with P. aeruginosa was established using the method of Starke et al. (30) . Previous studies from our laboratory demonstrated that PAO1, a well-characterized laboratory strain of P. aeruginosa, enmeshed in agar beads provides a reproducible example of a lethal infection in both C57BL/6 and BALB/c mice (29) . To establish a parallel model with a clinical strain of Pseudomonas, a similar model was assessed using PA514, PA515, PA516, and PA517. Based on the observation that PA514-impregnated agar beads gave the most reproducible lethal model, PA514 was used in all subsequent studies as an example of a clinical strain. Briefly, a log-phase bacteria diluted in warm (52°C) tryptic soy agar was added to heavy mineral oil and stirred vigorously, followed by cooling with ice. The bacteria-containing beads were washed extensively with PBS, and the number of viable P. aeruginosa in beads was determined by plating serial dilutions of homogenized bead suspension. Anesthetized mice were placed in a supine position, and 50 µl of 2 × 10 5 CFU Pseudomonas-impregnated beads was inoculated via the trachea into the lung. All animals were monitored daily for 14 days after the inoculation. Mice that appeared moribund were sacrificed, and this was recorded as the date of death.
In vitro proliferation and cytokine assays. Splenic CD4 + T cells were collected from mechanically disrupted spleens of immunized mice using anti-CD4 magnetic beads (Miltenyi Biotec, Auburn, California, USA). Proliferation and cytokine release by CD4 + T cells was assessed using 96-well plates with 5 × 10 4 microbe-pulsed DCs as stimulators and 5 × 10 5 immunized CD4 + T cells as responders in complete RPMI-1640 media. Microbepulsed DCs were prepared by incubation with heatkilled PAO1, PA103, or E. coli (DC/bacteria ratio, 1:10) for 4 hours at 37°C, irradiated for 30 Gy, and washed extensively before use. Cell proliferation was measured daily by an MTS colorimetric assay kit (Promega Corp., Madison, Wisconsin, USA) and calculated as 100 × Statistics. All data are reported as mean plus or minus SE, unless otherwise described. Statistical comparison was made using the two-tailed student's t test, and a P value of less than 0.05 was accepted as indicating significance. Survival evaluation was carried out using Kaplan-Meier analysis as described previously (29) .
Results
Genetic modification of DCs. Genetic modification of DCs by AdMDC resulted in high levels of exogenous MDC mRNA expression, but in no detectable change in the low level of endogenous MDC mRNA expression (Figure 1 ). Serial dilutions of the cDNA prepared from AdMDCmodified, AdNull-modified, or naive DCs were subjected to PCR amplification with primer sets specific for AdMDC-derived MDC mRNA, endogenous MDC mRNA, or ubiquitously expressed GAPDH mRNA. Exogenous MDC mRNA expression was detected at high levels only in AdMDC-modified DCs; this AdMDCderived transcript was strongly amplified even from cDNA diluted 100-fold. In contrast, similar low levels of endogenous MDC mRNA expression were found in these DCs with or without genetic modification. Comparable levels of expression of the housekeeping gene GAPDH demonstrated the intactness of the RNA samples.
The function of the MDC protein produced by AdMDC vector-modified DCs was confirmed by chemotaxis assays using human and murine T cell lines in vitro and by immunohistochemistry in vivo (Figures 2 and 3) . A dosedependent migratory response of human T lymphocyte CEM was observed only in the culture supernatant of AdMDC-modified DCs, but not in that of AdNull-modified or naive DCs (Figure 2a) . Similar results were achieved in the migration assay of murine T lymphocyte EL4, although the peak migration of EL4 cells against the supernatant of AdMDC-modified DCs was less intense (Figure 2b RT-PCR analysis for exogenous and endogenous MDC mRNA expression in genetically modified DC. Total cellular RNA (1 µg) from DCs transduced with AdMDC, AdNull, or PBS alone (naive control) were reverse transcribed using the oligo(dT) 18 primer. Serial 1:10 dilution of RT-generated cDNA were used as a template to amplify exogenous MDC, endogenous MDC, and GAPDH cDNA fragments by PCR. Samples were separated by 1.5% agarose gel electrophoresis and stained with ethidium bromide.
Ad-mediated MDC expression was demonstrated by the observation that both human and murine T lymphocyte chemotactic activities of the AdMDC-conditioned media were significantly inhibited by an addition of neutralizing anti-human MDC mAb to the media (CEM, P < 0.001; EL4, P < 0.005), but unaffected by that of isotype-matched control Ab (CEM, P > 0.5; EL4, P > 0.5; Figure 2c ). Furthermore, when recombinant human MDC or TARC was added in the upper chambers to disturb the gradients, the induced chemotaxis of both human and murine T cells was also suppressed using CEM and EL4 cells (rMDC: CEM, P < 0.001; EL4, P < 0.001; rTARC: CEM, P < 0.005; EL4, P < 0.01; Figure 2c ). The in vitro chemoattracting activity was relevant in vivo because cells expressing CCR4, a receptor for MDC, were observed around AdMDC-modified DCs in the spleen of the mouse 4 days after administration of AdMDC-modified and PKH26-labeled DCs (Figure 3a) . In contrast, no CCR4-positive cells were observed around AdNull-modified and PKH26-labeled DCs ( Figure 3b ). Surface phenotype of AdMDC-modified DCs. Characteristic DC surface molecules did not change significantly following DC modification with AdMDC ( Figure 4) . Interestingly, the surface markers MHC class II, CD40, B7-1, and B7-2 in DCs modified with AdMDC remained stable in cultures for 5 days without growth factors, while these surface markers diminished in control DCs in the same conditions. DCs generated with GM-CSF and IL-4 were transduced with AdMDC or AdNull vectors and then cultured for 5 days without GM-CSF and IL-4 to analyze for their expression of I-A b (MHC class II) and CD40 by two-color FACS analysis (Figure 4a ). Compared with DCs before subsequent culture without growth factors, the percentages of positive cells for both I-A b and CD40 were consistently higher in AdMDCmodified DCs (I-A b+ 76% vs. AdMDC 86%; CD40 + 58% vs. AdMDC 65%; I-A b+ CD40 + 48% vs. AdMDC 60%). The comparable percentage expression of these surface molecules was strikingly lower in AdNull-modified DCs (I-A b+ , 76% vs. AdNull 18%; CD40 + 58% vs. AdNull 24%; I-A b+ CD40 + 48% vs. AdNull 7%). Similar results were observed with CD80 (B7-1) and CD86 (B7-2) expression ( Figure 4b ). There was considerable variance in the percentages of positive cells for CD80 and CD86 between AdMDC-and AdNull-modified DCs cultured for 5 days in the absence of growth factors (CD80 + AdMDC 42% vs. AdNull 15%; CD86 + AdMDC 20% vs. AdNull 12%; CD80 + CD86 + AdMDC 19% vs. AdNull 9%), although these percentages of AdMDC-transduced DCs were slightly lower than that before the cytokine-depleted culture (CD80 + 46% vs. AdMDC 42%; CD86 + 30% vs. AdMDC 20%; CD80 + CD86 + 25% vs. AdMDC 19%).
In vivo protective effects of AdMDC-modified DCs. C57BL/6 and BALB/c mice immunized with AdMDC-modified DCs pulsed with P. aeruginosa were protected against
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The Where indicated, anti-MDC neutralizing Ab or mouse IgG control Ab was added to the supernatant in the lower chambers at 10 µg/ml at the initiation of assay or cells were placed to the upper chamber in the presence of recombinant (r) MDC or TARC at 100 ng/ml. For all parts, the number of cells migrating to the lower chamber at 37°C for 4 hours was counted by FACS analysis. Migration index was calculated as the number of cells migrating to the conditioned media over the number of cells migrating to control medium. Results represent the mean ± SE (n = 3 per data point).
Figure 3
Chemoattracting activity of AdMDC-modified DCs for CCR4-expressing cells in vivo. To demonstrate the in vivo function of AdMDC-modified DCs, C57BL/6 mice were intravenously injected with AdMDCor AdNull-modified DCs. Genetically modified DCs were labeled with PKH26 (red fluorescence) before the injection for in vivo cell tracking. After 4 days, spleens were dissected, and frozen spleen sections were stained using rabbit anti-mouse CCR4 Ab followed by visualization with anti-rabbit IgG Ab labeled with FITC (green fluorescence). Nuclei were stained with DAPI (blue fluorescence).
lethal Pseudomonas bronchopulmonary infection ( Figure  5 , a and b). Immunization of C57BL/6 mice with AdMDC-modified DCs pulsed with heat-killed P. aeruginosa provided complete survival against a lethal challenge with Pseudomonas-impregnated (PAO1 strain) beads (P < 0.001, AdMDC-modified DCs pulsed with P. aeruginosa compared with all other groups; Figure 5a ). In contrast, only 20% of mice immunized with AdNull-modified DCs pulsed with P. aeruginosa were protected, and immunization with AdMDC-modified DCs alone or no immunization resulted in no survival against the lethal challenge of P. aeruginosa. Similar results were achieved with immunized BALB/c mice ( Figure 5b ). BALB/c mice undergoing immunization of AdMDC-modified DCs pulsed with heat-killed P. aeruginosa also completely survived the lethal infection of Pseudomonas, whereas immunization with AdNull-modified DCs pulsed with P. aeruginosa, AdMDC-modified DCs alone, or no immunization led to only 30% or no survival, respectively, of the challenged mice (P < 0.005, AdMDC-modified DCs pulsed with P. aeruginosa compared with all other groups; Figure  5b ). We obtained similar results using genetically modified DCs that were stimulated by triggering CD40 with the agonist Ab against CD40 before administration: AdMDC-or AdNull-modified DCs pulsed with heatkilled P. aeruginosa provided 80% or 10% protection of immunized C57BL/6 mice, respectively (not shown). Anti-pseudomonas Ab responses. Enhanced serum levels of anti-Pseudomonas Ab's were observed in AdMDC/ DC/Pseudomonas-immunized mice, and its in vivo relevance was determined ( Figure 6 ). In all Ab isotypes examined, immunization with AdMDC-modified DCs pulsed with heat-killed Pseudomonas significantly increased the end-point titers of anti-Pseudomonas Ab on day 14 after immunization compared with all other control groups (IgM, P < 0.0005, Figure 6a ; IgG1, P < 0.005, Figure 6b ; IgG2a, P < 0.0005, Figure 6c ; IgG2b, P < 0.0005, Figure 6d ; IgG3, P < 0.01, Figure 6e ; IgA, P < 0.01, Figure 6f ). Controls included immunization with AdNull-modified DCs pulsed with heatkilled Pseudomonas, AdMDC-modified DCs alone, and no immunization. This observed difference in antiPseudomonas Ab levels was sufficient to protect recipient mice from a lethal infection of P. aeruginosa in passive transfer of serum (Figure 6g ). Passive transfer of 100 µl serum collected 3 weeks after immunization of AdMDC-modified DCs pulsed with P. aeruginosa resulted in 80% protection from a lethal challenge of P. aeruginosa (P < 0.005, AdMDC-modified DCs pulsed with P. aeruginosa compared with all other groups, Figure 6g ). Control serum from mice immunized with AdNullmodified DCs pulsed with P. aeruginosa or AdMDCmodified DCs alone mediated no protection, nor did no transfer of serum.
Transferable immunity in splenocytes. whether the AdMDC/Pseudomonas/DC-mediated protection against P. aeruginosa resides in the spleens of immunized mice, mice were adoptively immunized with 5 × 10 7 splenocytes isolated 2 weeks after preimmunization of AdMDC-modified DCs pulsed with P. aeruginosa and 7 days before an intratracheal instillation of Pseudomonas to the recipient mice (Figure 7a ). Spleen cells from mice preimmunized with AdMDCmodified DCs pulsed with Pseudomonas completely protected the recipient mice against a lethal infection (P < 0.0001, compared with all other groups). In contrast, control splenocytes from mice immunized with AdNull-modified DCs pulsed with Pseudomonas or AdMDC-modified DCs alone mediated no protection of recipients, nor did no transfer of splenocytes. To assess the pivotal cell components for this transferable immunity, CD4 + or CD8 + T cells were separated from the spleens of mice immunized with AdMDC-modified DCs pulsed with Pseudomonas, and each cell collection was transferred to naive recipient mice to determine its protective ability against lethal infection of P. aeruginosa (Figure 7b ). Adoptive transfer of splenic total splenocytes or CD4 + T cells of AdMDC/ Pseudomonas/DC-immunized mice provided 90% or 80% protection, respectively, against Pseudomonas challenge to recipient mice. In contrast, only 30% of mice adoptively receiving CD8 + T cells were protected (P < 0.05, CD4 + cells compared with CD8 + cells; P < 0.001, CD4 + cells compared with naive mice; P > 0.06, CD8 + cells compared with naive mice).
Th2-dominant humoral immunity.
Using relevant knockout mice, we observed that the AdMDC/Pseudomonas/DC immunization required CD4 + T lymphocytes, B lymphocytes, MHC class II antigen presentation of administrated DCs, and the ability to produce IL-4 (i.e., Th2 T cells), but not IL-12 (i.e., Th1 T cells; Figure 7 , c, d, and e). In this context, wild-type, CD8 + T cell-deficient (CD8 -/-), CD4 + T cell-deficient (CD4 -/-), and B cell-deficient (B cell -/-) C57BL/6 mice were immunized with AdMDC-modified DCs pulsed with P. aeruginosa, and after 3 weeks, challenged with intratracheal instillation of Pseudomonas-impregnated beads (Figure 7c ). Survival of CD4 -/-and B cell -/-mice was not improved by the AdMDC/Pseudomonas/DC immunization compared with that of nonimmunized wild-type mice, whereas immunized CD8 -/-mice were significantly protected from Pseudomonas challenge, comparable to that of immunized wild-type mice (P > 0.9 or P > 0.3, CD4 -/-or B -/-mice compared with nonimmunized wild-type mice, respectively; P < 0.0005, CD8 -/-mice compared with CD4 -/-, B -/-, and nonimmunized wild-type mice).
To assess the role of MHC antigen presentation by DCs in the AdMDC/Pseudomonas/DC immunization strategy, DCs were prepared from wild-type, MHC class I-deficient (class I -/-), or MHC class II-deficient (class II -/-) C57BL/6 mice for AdMDC modification and Pseudomonas pulse and used to immunize wild-type C57BL/6 mice with these MHC-deficient DCs 3 weeks before Pseudomonas challenge (Figure 7d) . When modi-
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The fied with AdMDC and pulsed with Pseudomonas, class II -/-DCs provided only partial protection against Pseudomonas challenge (30%), which was not significantly different from the result with nonimmunized wild-type mice, but immunization with class I -/-DCs was completely protective as wild-type DCs (P > 0.7, class II -/-DCs compared with nonimmunized wild-type mice; P < 0.005, class I -/-DCs compared with class II -/-DCs and nonimmunized wild-type mice). The specificity of Th1 and Th2 responses involved in the protective immunity of the AdMDC/Pseudomonas/DC was assessed using IL-12 and IL-4 knockout mice, respectively. Since IL-12 or IL-4 is a critical cytokine for the differentiation of naive CD4 + T cells to the Th1 or Th2 subset, respectively, the survival of immunized wildtype, IL-12-deficient (IL-12 -/-) or IL-4-deficient (IL-4 -/-) C57BL/6 mice was assessed after the challenge with Pseudomonas ( Figure 7e ). In IL-4 -/-mice, the AdMDC/Pseudomonas/DC immunization was not significantly different than nonimmunization in the protection of mice from challenge of Pseudomonas (P > 0.1). In contrast, 100% or 80% of immunized wild-type or IL-12 -/-mice, respectively, survived until the end of the experiment on day 14 (P < 0.001 or P < 0.05, immunized wild-type or IL-12 -/-mice, respectively, compared with both IL-4 -/-and nonimmunized wild-type mice).
Microbe-specific immunity. The microbe specificity of protective immunity developed by AdMDCmodified DCs was ascertained using E. coli as a control (Figure 8) . Naive C57BL/6 mice and mice immunized with AdMDC-modified DCs pulsed with either P. aeruginosa or E. coli were challenged 3 weeks later with Pseudomonas-impregnated beads. Only Pseudomonas-pulsed DCs conferred complete protection; no protective effect was observed with E. coli-pulsed DCs (P < 0.001, AdMDC/DCs pulsed with P. aeruginosa compared with all other groups; P > 0.7, AdMDC/DCs pulsed with E. coli compared with naive mice; Figure 8a) . In marked contrast, when these immunized mice were challenged with a lethal intratracheal infection of 10 8 CFU E. coli, only E. coli-pulsed DCs were significantly protective with 70% mice surviving. All of naive mice and mice immunized with P. aeruginosa-pulsed DCs died within 2 days after the E. coli instillation (P < 0.005, AdMDC/DCs pulsed with E. coli compared with all other groups; P > 0.6, AdMDC/DCs pulsed with P. aeruginosa compared with naive mice; Figure 8b) .
Protection against different strains of Pseudomonas. Given that the AdMDC/Pseudomonas/DC immunity has been shown to be specific to P. aeruginosa and to provide no protection against another gram-negative bacteria (E. coli), we next determined whether the AdMDC/Pseudomonas/DC immunity was cross-protective for different strains of Pseudomonas (Figure 9 ). In these studies, C57BL/6 mice were immunized with AdMDC/DCs pulsed with wellcharacterized laboratory strains of Pseudomonas (PAO1, PAO-NP, PAK, and PA103; Figure 9 , a and b) or clinical strains of P. aeruginosa (PA514, PA515, PA516, and PA517; Figure 9 , c and d) 3 weeks before challenge with P. aeruginosa laboratory strain PAO1 (Figure 9, a and d strain PA514 (Figure 9 , b and c). All AdMDC/DC immunization with laboratory-characterized Pseudomonas strains led to significant improvement in survival of the PAO1-and PA514-challenged mice compared with naive mice, although there was some variation in the efficacy of protection among the Pseudomonas strains used in immunization (P < 0.0001 or P < 0.005, naive mice compared with all other groups; Figure 9 , a or b, respectively). In comparison, at least 60% of animals following AdMDC/DC immunization pulsed with the clinical strains of P. aeruginosa were significantly protected against PA514 challenge, whereas none of immunization with clinical isolated Pseudomonas strains influenced the survival of mice challenged with the PAO1 strain (P < 0.05 or P > 0.05, naive mice compared with all other groups; Figure 9 , c or d, respectively). Thus, while there is significant cross-strain protection, it is not absolute. Interestingly, the use of clinical strains as the immunogens appeared to afford less overall protection against challenge with the laboratory strains than did immunization with the laboratory strains.
CD4 + T cell responses in vitro.
When cocultured in vitro with DCs pulsed with the specific microbe used in immunization, CD4 + T cells from AdMDC/DC-immunized mice proliferated and secreted the Th2-associated cytokine IL-4 ( Figure 10 ). Splenic CD4 + T cells isolated from naive C57BL/6 mice or mice immunized with AdMDC-modified DCs pulsed with P. aeruginosa strain PAO1 or E. coli were stimulated in vitro with naive, PAO1-pulsed, PA103-pulsed, or E. coli-pulsed DCs. Only CD4 + T cells from AdMDC/DC/ PAO1-immunized mice responded to PAO1-pulsed DC. CD4 + T cells from both naive and AdMDC/DC/E. coli-immunized mice did not proliferate in the presence of PAO1-pulsed DCs (Figure 10a) . A similar proliferative response of each CD4 + T cell group was achieved using DCs pulsed with another P. aeruginosa strain, PA103 (Figure 10b ). In contrast, coculture of CD4 + T cells from the AdMDC/DC/E. coli-immunized mice with E. coli-pulsed DCs resulted in a strong proliferative response, whereas E. coli-pulsed DCs did not stimulate CD4 + T cell proliferation from the naive and AdMDC/DC/PAO1-immunized mice (Figure 10c ). Additional control experiments demonstrated that splenic CD4 + T cells from PAO1-immunized mice, naive mice, or E. coli-immunized mice did not proliferate after incubation with naive DCs (Figure 10d ). The microbespecific CD4 + T cell proliferation from immunized mice was reflected in the IL-4 level secreted from CD4 + T cells
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Figure 8
Immunization with AdMDC/DCs induces protective immunity specific to the pathogen used for pulsing DCs. (a) P. aeruginosa challenge. C57BL/6 mice were immunized with AdMDC-modified DCs pulsed with heat-killed P. aeruginosa or E. coli (25922 strain). After 3 weeks, immunized animals were infected intratracheally with 2 × 10 5 CFU P. aeruginosa PAO1 enmeshed in agar beads. (b) E. coli challenge. Immunization of mice was identical to that in a, but 10 8 CFU E. coli (25922 strain) were used for the intratracheal infection. For both parts, controls included mice without any immunization. Survival was recorded as the percentage of surviving animals (n = 10 mice per group).
Figure 9
Cross-protective immunity of AdMDC-modified DCs against laboratory or clinical strains of P. aeruginosa. 4 days after the initiation of the cocultures (Figure 10e Figure 10 , a-e).
Discussion
In this study, we hypothesized that DCs modified with a recombinant Ad vector expressing MDC would easily encounter rare T cells bearing specific TCR for a bacterial antigen displayed on the DC surface, resulting in stimulation of specific humoral immune responses that would protect the immunized host from the relevant microbe infection. Several pieces of evidence substantiate that this hypothesis is valid. Immunization with AdMDC-modified DCs pulsed with heat-killed P. aeruginosa led to complete protection against a subsequent lethal infection with P. aeruginosa in two different strains of mice. This beneficial effect was mediated by Pseudomonas-specific humoral immunity, and an involvement of Th2-dominant immune responses in its generation was suggested by observation with in vivo immunization-infection models using knockout mice and in vitro CD4 + T cell proliferation and cytokine analyses. Ab-mediated humoral immunity is the principal specific immune response to defend a host against pathogenic extracellular bacteria (31). Whereas non-protein antigens such as polysaccharides and glycolipids induce low-affinity Ab responses without a requirement for CD4 + T cell help, competent Ab responses against conventional protein antigens require that B cells contact activated (i.e., antigen-specific) CD4 + T cells to be stimulated by multiple ligand-receptor pairs such as CD40 on B cells and CD40 ligand on activated CD4 + T cells (31) . In this context, extracellular microbial protein antigens that are endocytosed, processed, and presented in association with MHC class II molecules by antigen-presenting cells, especially DCs, enable antigen-specific CD4 + T cells to proliferate clonally, develop into memory cells, and differentiate to subsets of Th1 and Th2 effector T cells (1-3) . Therefore, the direct interaction of DCs and T cells is of central importance in initiating specific immune responses (1, 2) . This is achieved not only by the DCs migrating to the T cell-rich area of lymphoid organs, but also by the DCs themselves secreting T cell-attracting chemokines such as MDC (1, 2, 11, 16) . Recently, MDC has been shown in vitro and in vivo to attract subsets of activated T cells, in particular Th2 CD4 + Th cells, but not naive T cells, suggesting that MDC may enhance the encounter of antigenspecific T cells with antigen-bearing DCs and thus retain the interactions for a longer time to complete the T
Figure 10
Responses of CD4 + T cells from immunized mice in a microbe-specific manner. (a-d) Proliferation. C57BL/6 mice were immunized with AdMDC-modified DCs pulsed with P. aeruginosa PAO1 strain or E. coli. Three weeks after immunization, splenic CD4 + T cells were isolated from immunized or nonimmunized mice using the magnetic beads. In 96-well culture plates, 5 × 10 5 CD4 + T cells were stimulated with 5 × 10 4 DCs that had been pulsed with heat-killed P. aeruginosa strain PAO1 (a), heat-killed P. aeruginosa strain PA103 (b), heatkilled E. coli (c), or without any microbes (d), and irradiated. In (a-d), controls included DC culture without CD4 + T cells. The number of viable cells was determined using the MTS assay, as described in Methods. The data are presented as the mean percentage increase over baseline of duplicate wells. (e) IL-4 secretion. The culture medium was collected 4 days after the initiation of the coculture described above, and the levels of murine IL-4 were assayed by ELISA. The data are presented as means ± SE (n = 3 per data point).
cell-stimulation process. Consistent with this knowledge, the present study has demonstrated that genetic engineering of bacteria-pulsed DCs to express MDC efficiently induced bacterial antigen-relevant humoral immune responses with MHC class II-restricted and type 2-dominant CD4 + T cell help, resulting in protection of immunized mice against a relevant lethal infection. When administrated in vivo for the immunization, DCs that have been modified with AdMDC and pulsed with heatkilled bacteria most likely migrate to lymphoid organs and present processed protein antigens of bacterial origin on MHC class II molecules. In the context of the present study, Ad vector-mediated MDC probably enhanced the rate of encounter of antigen-presenting DCs and antigenspecific CD4 + T cells, thus more efficiently amplifying the relevant antigen-specific immune responses. In addition, the novel observation that AdMDC-transduced DCs helped maintain the surface phenotypes characteristic of DCs during in vitro culture, including MHC class II and CD40 molecule expression, may help explain one of the mechanisms by which this strategy of AdMDC/DCs pulsed with pathogenic microorganisms provides in vivo protective immunity.
Although the MDC receptor CCR4 (preferentially expressed by T lymphocytes, especially the Th2 subset of CD4 + Th cells), is the only receptor identified thus far for MDC, the following evidence from the literature and the present study suggests there are yet unidentified additional receptors for MDC. First, MDC can fully desensitize and abrogate a calcium flux in CCR4-transfected cells by a subsequent stimulation of TARC, another CCR4 ligand (9). In contrast, TARC only partly inhibits calcium mobilization of a subsequent response to MDC. This partial blocking effect of TARC was also demonstrated in the T cell chemotaxis assays of the present study. Second, monocytes and DCs, both of which express little or no CCR4, respond to MDC by chemotaxis (5, 12) . In the present study, we also observed that MDC helped maintain the differentiated state of the DCs in culture. Third, NH 2 terminally truncated MDC loses chemotactic activity for the T cell line HUT-78 (CCR4 + ), but retains its capacity to attract monocytes (CCR4 -) and anti-HIV-1 activity (32, 33) . Finally, murine MDC also binds to a second, unknown receptor on a separate T cell population, which is not recognized by murine TARC (34) . The possible diversity of receptors for MDC appears to suggest a novel activity of MDC. In this regard, MDC has been shown to enhance the phagocytic and killing activities of macrophages in vitro and to protect mice in experimental E. coli sepsis by the innate immune responses in vivo (35) . In regard to the present study, the mechanism whereby AdMDC-modified DCs exerted a microbe-specific protection in vivo can not be fully explained by nonspecific activation of macrophages, but could depend, in part, on MDC-induced increased bactericidal activity of phagocytic leukocytes.
In regard to clinical relevance of the AdMDC/DC strategy described in the present study, DCs genetically modified to overexpress MDC would require close monitoring, since excessive Th2 development could theoretically be associated with pathogenesis of atopic diseases, such as atopic dermatitis, asthma, and hay fever (36) . In this context, high levels of MDC have been detected in the sera of the majority of individuals with atopic dermatitis (37) , and overproduction of MDC and TARC has been reported in the atopic dermatitis-like lesions of NC/Nga mice (38) . In addition, Gonzalo et al. (19) have shown that, in a murine model of lung allergic inflammation, MDC expression is upregulated during the course of inflammation and that blockage of MDC with neutralizing Ab's results in prevention of airway hyperreactivity and significant reduction of eosinophils in the lung. In this context, the use of Ad vectors to genetically modify DCs with MDC is likely the optimal vector to use, since Ad vector-mediated expression of transgenes are only of limited duration (39) (40) (41) .
It is conceivable that in vivo MHC class II-and CD4 + T cell-dependent protective immunity of bacteria-pulsed AdMDC/DCs and in vitro CD4 + T cell proliferation cocultured with bacteria-pulsed DCs were mediated by bacterial superantigens rather than by conventional protein antigens (42) . Superantigens directly bind to class II MHC molecules outside the peptide-binding clefts without any intracellular processing and can interact with less restricted structural determinants of the TCR Vβ domain, leading to a massive polyclonal expansion of T cells bearing multiple distinct variable regions of TCRs (42) . However, this scenario is highly unlikely for several reasons. First, although in the murine MHC class II-TCR system, class II MHC molecule I-E is required for the presentation of viral and bacterial superantigens, AdMDC/ Pseudomonas/DC-mediated protection against the subsequent P. aeruginosa infection did not depend on whether immunized mice were in an I-E negative strain (C57BL/6) or an I-E positive strain (BALB/c) (42, 43) . Second, although exotoxin A, the only superantigen identified from P. aeruginosa, is structurally different between the PAO1 and PA103 strains, immunization with PA103-pulsed AdMDC/DCs brought about cross-reactive protection against a lethal challenge of PAO1. Third, Matsumoto et al. (44) have shown that intraperitoneal injection of heat-killed P. aeruginosa does not increase the serum anti-exotoxin A Ab level despite the improved survival rate in a murine gut-derived sepsis model, suggesting that superantigens of heat-killed Pseudomonas have no antigenic activity to induce a marked production of specific Ab's such as that observed in mice immunized with AdMDC/DCs pulsed with heat-killed Pseudomonas. Finally, Kersten et al. (45) have identified conventional protein antigens that are specific either for P. aeruginosa or E. coli and can be recognized by TCR. Taken together, such microbe-specific antigens derived from MHC-restricted conventional proteins may be responsible for the results observed in the in vivo immunization-challenge experiments in the present study, as well as in vitro CD4 + T cell analyses. However, it is unclear why AdMDC/DCs pulsed with clinical strains of Pseudomonas could not protect against subsequent challenge with PAO1, a well-charac-terized laboratory strain of P. aeruginosa, despite other well cross-reactivity among laboratory and clinical P. aeruginosa strains. The elucidation of these mechanisms awaits further studies characterizing clinical Pseudomonas strains used in this study more definitely and identifying responsible antigens for immunization with AdMDC/DCs.
